Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2025-275-b-S | Other Identifier | Ethikkommission Westfalen-Lippe |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Deutsche Krebshilfe e.V., Bonn (Germany) | OTHER |
| University Hospital, Bonn | OTHER |
| University Hospital Dresden | OTHER |
Not provided
Not provided
Not provided
Not provided
In weekly expert meetings for oncological diagnostics and therapy, known as tumor boards, individual therapy recommendations are developed for cancer patients. By further developing and optimizing the CCCs' video tumor boards, initially using skin cancer as an example, we want to ensure that more patients can benefit from the expertise of several specialist disciplines and innovations - regardless of where they live.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Retrospective | ||
| 2 | Prospective |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Presentation of external patients in the video-tumorboard | Increase in the proportion of external patients in the video-tumorboard | Day 365 |
| Measure | Description | Time Frame |
|---|---|---|
| Increase in the proportion of external patients invited to a clinical study | Increase in the proportion of external patients in clinical studies | Day 365 |
| Adherence to tumorboard recommendations for external patients |
Not provided
Inclusion Criteria:
Inclusion criteria for patients:
Minimum age 18 years
Consent to participate in the study (signing of patient consent) should be presented in vTB+ according to the doctor, based on the disease/diagnosis, especially in the case of:
In this case, revenue/cost aspects and the DKG requirement are ignored. This means that so-called external patients can also be treated at the center, including initiation of therapy. The decisive factor is the presentation of the external patient (personal presentation of the external patients is not mandatory) and that external co-treaters are consistently informed and involved.
Inclusion criteria for external doctors:
Exclusion Criteria:
Patients will be excluded from the study if they meet the following criteria:
Not provided
Not provided
Not provided
As part of the vTB+ study, an evaluation of the video tumor board is to be carried out for as broad a section of the population as possible. Women of childbearing potential with and without contraception make up a relevant proportion of the population. Participation in the study is not associated with physical interventions, so that the contraceptive status of fertile participants is irrelevant. Even in the case of pregnancy, participation in the study would be harmless. The exclusion of women of childbearing potential with and without contraception from the vTB+ study would therefore represent a gender-based disadvantage.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Philipp Lenz, MD | Contact | +49 251 83 43745 | philipp.lenz@ukmuenster.de | |
| Friedegund Meier, MD | Contact | +49 351 4583677 | friedegund.meier@ukdd.de |
| Name | Affiliation | Role |
|---|---|---|
| Philipp Lenz, MD | Westdeutsches Tumorzentrum Münster, Universitätsklinikum Münster | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Abteilung für Integrierte Onkologie - CIO Bonn, Universitätsklinikum Bonn | Not yet recruiting | Bonn | 53127 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008545 | Melanoma |
| ID | Term |
|---|---|
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
Proportion of implemented tumorboard recommendations for external patients
| Up to two weeks after inclusion |
| Offer of supportive therapies by the comprehensive cancer center | Proportion of (external) patients who are offered at least one supportive therapy (e.g. psychooncology) within the video-tumorboard | Up to two days after inclusion |
| Duration of the transmission of the tumorboard recommendations | Duration of the transmission of the tumorboard recommendations | Up to two weeks after inclusion |
| "Time to integration" into palliative care | Time between medical recommendation for palliative care and first contact with palliative care | Once per patient within two weeks after transmission of the tumorboard recommendation if applicable |
| Nationales Centrum für Tumorerkrankungen Klinik u. Poliklinik für Dermatologie, Universitätsklinikum Dresden | Recruiting | Dresden | 01099 | Germany |
|
| Westdeutsches Tumorzentrum Münster, Universitätsklinikum Münster | Not yet recruiting | Münster | 48149 | Germany |
|
| D009369 | Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D012878 | Skin Neoplasms |
| D009371 | Neoplasms by Site |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |